Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis
Article 2014 en
Authors
PS
Per Soelberg Sørensen
SL
Steen Lisby
RG
Richard Grove
Abstract
1 min read
This study provides Class II evidence that in patients with RRMS, ofatumumab compared with placebo does not increase the number of serious adverse events and decreases the number of new MRI lesions.
Frauke Zipp, HP Hartung, Jan Hillert, Sebastian Schimrigk, Corinna Trebst, Martin Stangel, Carmen Infante‐Duarte, Peter Jakobs, Christian Wolf, Rupert Sandbrink, Christoph Pohl, Massimo Filippi
Gıancarlo Comı, Timothy R. Vollmer, Xavier Montalbán, Tjalf Ziemssen, Alexey Boyко, Patrick Vermersch, Tamar Rachmilewitz, Noah J. Sasson, Tali Gorfine, Volker Knappertz, Maria A. Rocca, Massimo Filippi
Andrew R. Pettitt, Nagesh Kalakonda, Fotis Polydoros, M. Bickerstaff, Geetha Menon, Sarah E. Coupland, M Oates, Ke Lin, Chris Pocock, Stephen Jenkins, Anna Schuh, Farooq Wandroo, Sal Rassam, Andrew Duncombe, Matthew Jenner, P. Cervi, Shankara Paneesha, Maadh Aldouri, Christopher P. Fox, C. Knechtli, Michael R Hamblin, ,
Discussion(0)
No comments yet. Be the first to comment.